{'_data': [['Unknown',
            [['Blood',
              u'Very rarely, thrombocytopenia. Post-marketing Safety Study In a post-marketing safety study, a total of 29,587 individuals >18 years of age received 1 or 2 doses of VAQTA. There was no serious, vaccine-related, adverse event identified. There was no nonserious, vaccine-related, adverse event resulting in outpatient visits, with the exception of diarrhea/gastroenteritis in adults at a rate of 0.5%.']]]],
 '_pages': [5, 7],
 u'_rank': 1,
 u'_type': u'LSFU'}